Clinical Trial Update: Annexin A5 in Patients With Severe COVID-19 Disease [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating Annexin A5 in patients with severe COVID-19 disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronavirus Infection
• Sepsis

Drugs mentioned

• Annexin A5 (annexin A5)

Snippet

Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Conditions: Coronavirus Infection, Sepsis | Phase 2 | Status: COMPLETED